10-Year Survival Similar With Chemoradiation or Surgery in Resectable Advanced NSCLC
Apr 09, 2026
Ten-year follow-up of the phase 3 ESPATUE trial found similar overall and progression-free survival with chemoradiotherapy boost or surgery in resectable advanced NSCLC after induction therapy.